Evidence map›Paper›PMID 32721120›Full record

ArticleCancer reports (Hoboken, N.J.)2020

A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures.

Pia Hoellerbauer, Megan Kufeld, Sonali Arora, Hua-Jun Wu, Heather M Feldman, Patrick J Paddison

Open access · hybridAbstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. NAR cancer · 2024
    Article
  5. Article
  6. An End-to-endProceedings. IEEE International Conference on Healthcare Informatics · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Pia HoellerbauerHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Megan KufeldHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Sonali AroraHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Hua-Jun WuDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA.
Heather M FeldmanHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Patrick J PaddisonHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID 0000-0002-7144-0228
Fred Hutch Cancer Center · USUniversity of Washington · USCancer Research And Biostatistics · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
CORE--VECTOR PRODUCTIONP30DK056465 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BERNSTEIN, IRWIN D · 1999 to 2014
$14.9M
Interdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
MYC-dependent loss of splicing fidelity in Glioblastoma multiformeR01CA190957 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PADDISON, PATRICK · 2015 to 2019
$2.2M
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA190957NCI NIH HHS T32 CA080416NIDDK NIH HHS P30 DK056465NIDDK NIH HHS U54 DK106829
6 · The paper itself

Abstract

backgroundCRISPR-Cas9-based technologies have revolutionized experimental manipulation of mammalian genomes. None-the-less, limitations of the delivery and efficacy of these technologies restrict their application in primary cells.

aimsTo create an optimized protocol for penetrant, reproducible, and fast targeted genome editing in cell cultures derived from primary cells, using patient-derived glioblastoma stem-like cells (GSCs) and human neural stem/progenitor cells (NSCs) for proof-of-concept experiments. METHODS AND

resultsWe employed transient nucleofection of Cas9:sgRNA ribonucleoprotein complexes composed of chemically synthesized 2'-O-methyl 3'phosphorothioate-modified sgRNAs and purified Cas9 protein. Insertion-deletion mutation (indel) frequency and size distribution were measured via computational deconvolution of Sanger sequencing trace data. We found that this optimized technique routinely allows for >90% indel formation in only 3 days, without the need to create clonal lines for simple loss-of-function experiments. Using Western blotting, we observed near-total protein loss of target genes in cell pools. Additionally, we found that this approach allows for the creation of targeted genomic deletions. Furthermore, by using RNA-seq in edited NSCs to assess gene expression changes resulting from knockout of tumor suppressors commonly altered in glioblastoma, we also demonstrated the utility of this method for quickly creating a series of gene knockouts that allow for the study of oncogenic activities.

conclusionOur data suggest that this relatively simple method can be used for highly efficient and fast gene knockout, as well as for targeted genomic deletions, even in hyperdiploid cells (such as GSCs). This represents an extremely useful tool for the cancer research community when wishing to inactivate not only coding genes, but also non-coding RNAs, UTRs, enhancers, and promoters. This method can be readily applied to diverse cell types by varying the nucleofection conditions.

Indexed as

CRISPR-Cas SystemsGene EditingGene Knockout TechniquesGlioblastomaHumansNeoplastic Stem CellsPrimary Cell CultureProof of Concept StudyRNA-SeqCas9:sgRNA ribonucleoproteinCRISPR-Cas9gene editinggenomic deletionglioblastoma stem-like cellsneural stem cells

Identifiers

PMID32721120
PMCPMC7685144
OpenAlexW3045751052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.